Search results
Results from the WOW.Com Content Network
Insulin glargine sold under the brand name Lantus among others is a long-acting modified form of medical insulin, used in the management of type 1 and type 2 diabetes. [7] It is injected just under the skin. [7] Effects generally begin an hour after use. [7]
Umeclidinium bromide is a long-acting muscarinic antagonist. [14] This combination was approved by the FDA on December 18, 2013 [15] for the long-term maintenance treatment of COPD. On March 28, 2014, it was approved in European countries [16] and in Russia [17] under the same trade name.
This page was last edited on 2 December 2024, at 21:02 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Abasaglar, [94] Semglee [95] Insulin lispro: Humalog [96] ... Recombinant therapeutic proteins are of a complex nature (composed of a long chain of amino acids ...
Lixisenatide is used as adjunct to diet and exercise to treat type 2 diabetes. [3] In the European Union, its use is limited to complementing insulin therapy. [2] [4] As of 2017 it is unclear if they affect a person's risk of death.
Danish pharmaceutical company Novo Nordisk — who are also the makers of liraglutide — developed semaglutide as a long-acting type 2 diabetes drug. Semaglutide was first tested on mice, and ...
The combination of the fast-acting form and the long-acting form allows the patient to receive fewer injections over the course of the day. [27] NovoLog Mix is marketed to be used with the Novo Nordisk FlexPen. [28] The onset of action is less than 30 minutes, the peak action is reached in 1–4 hours, and the duration is less than 24 hours. [29]
According to a 2015 analysis, albiglutide is less effective than other GLP-1 agonists for lowering glycated hemoglobin (HbA 1c, an indicator for long-term blood glucose control) and weight loss. It also seems to have fewer side effects than most other drugs of this class, except for reactions at the injection site which are more common under ...